News

Capricor ALLSTAR Phase I Clinical Trial TCT 2014 Stem Cells Myocardial Regenerat

Capricor Therapeutics Inc. presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation...

September 15, 2014 — A new gene-directed drug being tested through a research study called GENETIC-AF may improve care, quality of life and survival in patients with heart failure and atrial...

stem cells, cytori, stem cell therapy

The Cardiovascular Cell Therapy Research Network (CCTRN), has selected Cytori Therapeutics, Inc. to supply adipose-derived regenerative cells (ADRCs) for a clinical trial aimed at...

Cedars-Sinai Heart Institute Clinic Heart Vascular Disease Stem Cell Studies

Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.

cormatrix, cardiovascular, cardiovascular repair

CorMatrix Cardiovascular announced that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix ECM for Vascular Repair.

CorMatrix Cardiovascular ECM Enrollment RESTORE Study Poland

CorMatrix Cardiovascular and the Central Clinical Hospital of the Ministry of Interior in Warsaw (Centralny Szpital Kliniczny MSW) of Warsaw, Poland, announced the successful enrollment and...

Capricor Therapeutics Inc. announced the execution of an Exclusive License Agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes. ...

Researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI) revealed how a protein encourages the production of stem cells that regenerate damaged tissues of...

FDA MSC Consortium Stem Cell Research

The U.S. Food and Drug Administration (FDA) MSC Consortium is a large team of FDA scientists studying adult mesenchymal stem cells (MSCs), which could eventually be used to repair, replace,...

April 30, 2014 — Celladon Corp. announced its lead product candidate, Mydicar, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing...

April 23, 2014 — Xeltis announced it finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural,...

Cytori Stem Cell Therapy Heart Failure Treatments PRECISE Trial

Cytori Therapeutics announced publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. 

April 18, 2014 — New research presented at the 34th annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) demonstrated the CorMatrix particulate extracellular...

Cardiac Stem Cells Regeneration Therapy

Generating new cardiac muscle from human embryonic stem cells (hESCs) and/or induced pluripotent stem cells (...

Cardiac stem cells regeneration therapy clinical trial study

Marty Greenfield lives with crushing pain every day due to angina. He has suffered a heart attack, and a coronary bypass procedure and angioplasty have provided little relief. His doctor referred...

Stem Cell Therapy Gene Cardiac Regeneration

After a heart attack, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after...

Ademedus CardioCel Stem Cell Therapy

The U.S. Food and Drug Administration (FDA) cleared Admedus’s CardioCel, a tissue product to repair and treat a range of cardiovascular and vascular defects. The company is looking to complement...

Scientists at Icahn School of Medicine at Mount Sinai may have developed a tissue model for the human heart that can bridge the gap between animal models and human clinical trial patients. Mount...

BioLeonhardt Implantable Stem Cell Pump Cath Lab Therapies Heart Failure

BioLeonhardt, a Leonhardt Ventures company based in Los Angeles, unveiled its implantable stem cell pump at the 9th Annual Cell Therapy for Cardiovascular Disease meeting at Columbia University,...

CorMatrix Cardiovascular Extracellular Matrix ECM Bioscaffold

CorMatrix Cardiovascular Inc. received a patent for an augmented injectable extracellular matrix (ECM) bioscaffold.